NTRA - Natera, Inc.
16.85 +0.30 (1.81%)
After hours: 6:49PM EST
| Previous Close | 16.17 |
| Open | 16.33 |
| Bid | 15.73 x 1000 |
| Ask | 17.00 x 1000 |
| Day's Range | 16.08 - 16.74 |
| 52 Week Range | 8.60 - 29.62 |
| Volume | 448,495 |
| Avg. Volume | 591,536 |
| Market Cap | 1.023B |
| Beta (3Y Monthly) | 2.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.57 |
| Earnings Date | Mar 11, 2019 - Mar 15, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.86 |
- PR Newswire•15 days ago
Natera Announces Agreement with One Lambda to Co-Distribute Its Kidney Transplant Rejection Test
Agreement Enhances Commercial Presence in Organ Transplant Centers SAN CARLOS, Calif. , Feb. 1, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis ...
- GlobeNewswire•25 days ago
Consolidated Research: 2019 Summary Expectations for Marathon Petroleum, AMC Entertainment, JetBlue Airways, Acceleron Pharma, Natera, and AquaVenture — Fundamental Analysis, Key Performance Indications
NEW YORK, Jan. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•last month
Natera Announces Publication of Kidney Transplant Validation Study, Demonstrating Superior Data in Detection of Clinical and Subclinical Rejection
Represents Successful Achievement of All 2018 Commercialization Milestones, on Path to 2019 Launch SAN CARLOS, Calif. , Jan. 7, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in cell-free ...
- PR Newswire•last month
Natera To Webcast Live Presentation at the 37th Annual J.P. Morgan Healthcare Conference
SAN CARLOS, Calif. , Jan. 4, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, today announced that it will webcast a live ...
- PR Newswire•last month
Natera Obtains Z-Codes for Signatera MRD and Treatment Monitoring Test in Oncology
Represents Key Reimbursement Milestone In Line with Planned Clinical Launch SAN CARLOS, Calif. , Jan. 4, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in non-invasive genetic testing ...
- PR Newswire•last month
Natera Appoints Steve Chapman CEO and Robert Schueren COO; Matthew Rabinowitz Moves to Executive Chairman
SAN CARLOS, Calif., Jan. 2, 2019 /PRNewswire/ -- Natera, Inc. (NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, has announced the appointment of Steve Chapman as Chief Executive Officer (CEO) effective today and Robert Schueren as Chief Operating Officer (COO) effective January 7, 2019. Previously, Chapman was the company's COO and will succeed Matthew Rabinowitz, Ph.D., Natera co-founder and CEO. Rabinowitz will remain integrally involved as Executive Chairman focusing on the company's long-term business strategy and technology innovation.
- Simply Wall St.•2 months ago
Who Has Been Selling Natera, Inc. (NASDAQ:NTRA) Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales have Read More...
Insider Monkey•2 months agoIs Natera Inc (NTRA) Going to Burn These Hedge Funds?
How do we determine whether Natera Inc (NASDAQ:NTRA) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows that […]
- PR Newswire•2 months ago
Natera Presents Breast Cancer Data at SABCS Showing Ability of Signatera (RUO) to Detect Molecular Residual Disease Up to Two Years Prior to Clinical Relapse and Predict Treatment Response
Study Demonstrates Utility of Assay in Neoadjuvant and Adjuvant Treatment Settings SAN CARLOS, Calif. , Dec. 6, 2018 /PRNewswire/ -- Natera , Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing ...
- PR Newswire•3 months ago
Natera Achieves Enrollment Goal of 20,000 Patients in SMART Study
SAN CARLOS, Calif., Nov. 29, 2018 /PRNewswire/ -- Natera, Inc. (NTRA), a global leader in cell-free DNA testing, today announced that it has enrolled 20,000 patients in the SMART (SNP-based Microdeletion and Aneuploidy Registry Trial) study, designed to evaluate the clinical utility of the company's Panorama® non-invasive prenatal test (NIPT) to screen for aneuploidies and microdeletion genetic conditions, such as 22q11.2 deletion syndrome (DiGeorge syndrome).
- GlobeNewswire•3 months ago
New Research: Key Drivers of Growth for Mersana Therapeutics, Maiden, Payment Data, CareDx, Natera, and Spero Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•3 months ago
Natera Receives Unique Z-Code for Its Kidney Transplant Rejection Monitoring Test
Represents a Key Milestone Towards Achieving Medicare Reimbursement SAN CARLOS, Calif. , Nov. 28, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced ...
- Zacks•3 months ago
PerkinElmer's Vanadis NIPT CE Mark Boosts Prenatal Prospects
PerkinElmer's (PKI) Vanadis NIPT is a more cost effective and non-invasive screening system compared to traditional ones.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of NTRA earnings conference call or presentation 8-Nov-18 9:30pm GMT
Q3 2018 Natera Inc Earnings Call
- GuruFocus.com•3 months ago
Earnings Results Make 3 Stocks Move Friday
CenturyLink, Natera fall, while Trade Desk jumps
- Zacks•3 months ago
Natera (NTRA) Reports Q3 Loss, Misses Revenue Estimates
Natera (NTRA) delivered earnings and revenue surprises of -6.52% and -2.38%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Natera: 3Q Earnings Snapshot
On a per-share basis, the San Carlos, California-based company said it had a loss of 49 cents. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...
- PR Newswire•3 months ago
Natera Reports Third Quarter 2018 Financial Results
SAN CARLOS, Calif. , Nov. 8, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for ...
Market Realist•3 months agoVeracyte Stock Witnesses Solid Growth after Its Q3 Results
Veracyte (VCYT) stock rose 22.46% on October 30 after it released its third-quarter earnings results on October 29. On October 30, Veracyte stock closed at $11.56, a ~22.46% rise from its previous day’s close of $9.44 on October 29.
- PR Newswire•3 months ago
Natera Announces Third Quarter 2018 Earnings Conference Call
SAN CARLOS, Calif. , Nov. 1, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release ...
American City Business Journals•4 months agoPremier Bay Area biotech developer tees up next major project
The developer behind some of the Bay Area's largest biotech and life sciences campuses is poised to begin construction on another on the Peninsula, which could become the next big biotech hub.
- PR Newswire•4 months ago
Natera and Neon Therapeutics Announce Clinical Trial Collaboration to Assess Treatment Response to Personal Cancer Vaccine
Combines Neon's Personal Neoantigen Vaccine and Signatera (RUO) Circulating Tumor DNA Biomarker in Metastatic Non-Small Cell Lung Cancer Trial SAN CARLOS, Calif. , & CAMBRIDGE, Mass. , Oct. 18, 2018 /PRNewswire/ ...
- GuruFocus.com•5 months ago
Natera Inc (NTRA) CEO Matthew Rabinowitz Sold $8.1 million of Shares
CEO of Natera Inc (NASDAQ:NTRA) Matthew Rabinowitz sold 324,844 shares of NTRA on 09/26/2018 at an average price of $24.85 a share.
